To estimate the age distribution of putatively causal HPV infections leading to CIN2+ in Canadian women, highlighting the significance of CIN2+ as a precursor to cervical cancer.
Key Findings:
The predicted median age at causal HPV infection was 24.9 years (95% CI: 24.3-26.1).
The predicted median age at CIN2+ diagnosis was 29.8 years (95% CI: 28.8-30.6).
84.1% of causal HPV infections occurred in women older than 18 years.
47.1% of causal HPV infections occurred in women older than 26 years.
Interpretation:
A significant percentage of causal HPV infections leading to CIN2+ occur in women aged 26 years or older, suggesting the need for extended vaccination programs to enhance public health outcomes.
Limitations:
The model relies on assumptions about the natural history of HPV and screening practices, which may not fully capture real-world variations.
Data may not fully represent all Canadian jurisdictions, potentially affecting the generalizability of the findings.
Conclusion:
Extending catch-up vaccination programs to women above age 26 years should be considered to prevent HPV-related cervical diseases, reinforcing the importance of vaccination in public health policy.
Investigative report cites internal communications, VAERS data, and CDC case reviews describing myocarditis and pericarditis reports in adolescents and young adults after mRNA COVID-19 vaccination.
